Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelial dysfunction, atherosclerosis and diabetes.

C Najemnik1, H Sinzinger, H Kritz

  • 1Wilhelm-Auerswald Atherosclerosis Research Group Vienna, Department of Nuclear Medicine, City Hospital Vienna-Lainz, Vienna.

Acta Medica Austriaca
|August 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Imaging of early carotid artery atherosclerotic lesions with 111In-labeled polyelonalhuman IgG (HIG)].

Nuklearmedizin. Nuclear medicine·2006
Same author

6-oxo-PGF(1 alpha)and 8-epi-PGF(2 alpha)in the arterial wall layers of various species: a comparison between intact and atherosclerotic areas.

Prostaglandins, leukotrienes, and essential fatty acids·2001
Same author

[HDL-2000: A consensus. HDL--a neglected lipoprotein].

Wiener klinische Wochenschrift·2001
Same author

Association of lipoprotein(a), prostaglandin I(2)--synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stages.

Prostaglandins, leukotrienes, and essential fatty acids·2000
Same author

[Unaltered homocysteine levels during simvastatin therapy].

Wiener klinische Wochenschrift·2000
Same author

Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation.

Prostaglandins, leukotrienes, and essential fatty acids·1999
Same journal

[Gestational diabetes mellitus].

Acta medica Austriaca·2005
Same journal

[Diagnosis, therapy and follow-up of diabetic eye diseases].

Acta medica Austriaca·2005
Same journal

[Diabetic nephropathy].

Acta medica Austriaca·2005
Same journal

[The diabetic foot].

Acta medica Austriaca·2005
Same journal

[Diabetic neuropathy].

Acta medica Austriaca·2005
Same journal

[Inhibition of platelet aggregation].

Acta medica Austriaca·2005
See all related articles

Diabetes and hypertension accelerate atherosclerosis, increasing morbidity and mortality. Restoring endothelial function through glycemic control, lipid management, and blood pressure normalization is key to preventing vascular complications.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Vascular Biology

Background:

  • Diabetes and hypertension significantly increase atherosclerosis risk, leading to high morbidity and mortality.
  • The precise mechanisms linking diabetes to vascular disease are unclear, but endothelial dysfunction is a key factor.
  • Endothelial dysfunction in diabetes involves lipoprotein modification, advanced glycation end-products, altered nitric oxide pathways, and elevated homocysteine.

Purpose of the Study:

  • To explore the role of endothelial dysfunction in diabetic vascular complications.
  • To identify therapeutic targets for restoring endothelial function in diabetic patients.
  • To highlight the clinical relevance of new findings in endothelial dysfunction.

Main Methods:

  • Review of existing literature on diabetes, hypertension, and atherosclerosis.

Related Experiment Videos

  • Analysis of pathophysiological conditions affecting the endothelium in diabetes.
  • Examination of therapeutic strategies aimed at improving endothelial function.

    • Main Results:

    • Diabetes and hypertension are strongly associated with early and accelerated atherosclerosis.
    • Endothelial dysfunction, characterized by specific molecular and cellular changes, is central to diabetic vascular complications.
    • Pharmacological agents can exert direct beneficial effects on the endothelium, improving endothelial dysfunction.

    Conclusions:

    • Restoring endothelial function is crucial for managing diabetic vascular complications.
    • Therapeutic strategies should focus on glycemic control, lipid management, blood pressure normalization, and addressing specific endothelial dysfunction pathways.
    • Emerging research on endothelial dysfunction holds significant potential for clinical applications in diabetes management.